Furthermore, combined ICI therapy poses a breakthrough in the treatment of some types of cancer, such as non-small-cell lung cancer and metastatic melanoma, in which the concomitant administration of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) increases the response rate and survival [6]. This evidence concerns the gene CTLA4 and cancer.